Flywheel, provider of cloud-based collaborative science solutions for biomedical research, today announced a technology partnership with Google Cloud to integrate Google’s Cloud Healthcare Application Programming Interface (API) with Flywheel’s platform to provide clinical researchers with advanced cloud technology for medical imaging research.

Breakthrough Cloud Platform and Machine Learning Technology to be Showcased at HIMSS19 in Orlando, Florida

Flywheel, the research informatics company, announces the deployment of its medical imaging research platform at Columbia University on Google Cloud Platform (GCP). The Flywheel platform has been used by the Columbia neuroscience and biomedical imaging community and their internal and external collaborators at Columbia’s Mortimer B. Zuckerman Mind Brain Behavior Institute since June 2017. With rapid user adoption and increased demands for largescale data management and computation, Columbia has expanded the Flywheel program and migrated to Google Cloud.

Innovative combination improves access, lowers cost and meets patients’ needs through technology and telehealth.

GeneMatters and Clear Genetics today announced they will offer a joint service that combines chatbots with live genetic counselors. The arrangement will help healthcare organizations enable more patients to receive genetic counseling in a consistent, timely and affordable manner, while allowing patients to drive the level of service they need.

OneOme, co-developed by Mayo Clinic, today announced several significant enhancements to its product offering, including the addition of four new genes (HLA-A, HLA-B, CYP4F2, and CYP2C Cluster) and nine new medications to its RightMed® comprehensive test, a pharmacogenomic (PGx) test that analyzes a patient’s DNA to predict how they will respond to hundreds of medications. In addition to these updates, OneOme now gives providers the option to order the MTHFR gene as a complimentary add-on to the RightMed test.

Save the date for our a spring investor open house. The event will be held Tuesday, May 15 from 5:00 - 7:30 PM. We look forward to seeing you and sharing the exciting progress of our portfolio companies.

MINNEAPOLIS, Feb 21, 2018 Invenshure portfolio company, OneOme, a healthcare technology company whose genetic test helps predict how a person will respond to hundreds of medications, announced it was named to Fast Company's World's 50 Most Innovative Companies list, as well as the Top 10 Most Innovative Companies in Biotech for 2018 in the publication's annual issue. OneOme numbered second in the Top 10 in biotech category and 22nd of 50 in the overall list.

Flywheel Exchange LLC, the collaborative science platform company, has entered into an agreement with Brain Vision, LLC to develop and sell data management for the neurophysiological research community. This solution will be the world’s first web-based automatic data capture from an electroencephalography (EEG) recording software to a central, cloud-scale database.

Flywheel, the collaborative science software company, announces the implementation of the Flywheel Center Edition at Columbia University. The system was designed for use by Columbia’s neuroscience community and their collaborators around the world, and will provide the foundation for a new paradigm in imaging research that brings together different expertise and disciplines.

The Concierge Medicine Forum held this week in Atlanta will feature an expert on pharmacogenomics from OneOme, a leading precision medicine company. Ryan Gregg, Ph.D, medical science liaison from OneOme, will present a session on pharmacogenomics on Friday, October 27, at 11:05 a.m. at the Forsyth Conference Center in Cumming, Georgia. Pharmacogenomics is an emerging field that identifies how a patient’s unique DNA and current medications may affect their response to medications.

In Singapore, OneOme and Tucker Medical are working together to help improve preventive care and oncology treatments. OneOme is a leader in pharmacogenomic testing and Tucker Medical is a multi-specialty practice offering personalized medicine and care in medical oncology, gastroenterology, and family medicine.

Today, OneOme announced it has been named a finalist for the 18th Annual Minnesota High Tech Association (MHTA) Tekne Awards in the Healthcare category. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership. OneOme’s RightMed® pharmacogenomic solution identifies how a patient’s DNA and current medications may affect their response to medications.

Next week, OneOme will participate in the Individualizing Medicine 2017 Conference in Rochester, Minn. The event, which is hosted by the Mayo Clinic Center for Individualized Medicine, features experts from around the world sharing advice on the practical application of genomic and precision medicine.

MINNEAPOLIS (October 5, 2017) – OneOme today launched several significant upgrades to its RightMed® pharmacogenomics solution. The RightMed solution now includes an additional gene (SLC6A4), a streamlined psychiatry report, a secure tool for patients to share their results with other providers, and insurance billing. The upgrades expand the utility of OneOme’s RightMed comprehensive test and supporting products.

Today, OneOme and Rainbow Genomics announced they are teaming up to provide genomic services to patients in Hong Kong, Japan, and Macau. OneOme’s RightMed® pharmacogenomic test will be offered alongside Rainbow Genomics’ whole exome sequencing test services. The full OneOme RightMed platform – which identifies how a patient’s DNA and current medications may affect their response to drugs – will be offered by Rainbow Genomics to patients and physicians.

MINNEAPOLIS (August 22, 2017) – On Wednesday, August 23 and Thursday, August 24, OneOme’s director of laboratory operations, Ross Higgins, will speak about the barriers and opportunities for implementing pharmacogenomics in clinical medicine at the Precision Medicine Leaders Summit in San Diego. The event, which features influential precision medicine innovators from across the world, takes place at the Hilton San Diego Bayfront hotel.

Minneapolis, Minnesota; North Bay, Ontario (July 26, 2017) – A new partnership between OneOme and ProZed Pharmacy Solutions brings the power of personalized medicine to Canada. Minnesota-based OneOme will provide its RightMed® pharmacogenomics platform exclusively to customers of ProZed Pharmacy Solutions at Northern Shores Pharmacy in North Bay, Ontario as the first step in a nationwide launch. The partnership is the precision medicine company’s first entry into the Canadian retail pharmacy market.

MINNEAPOLIS, MEXICO CITY (July 13, 2017) – Pharmacogenomics leader OneOme today announced it has forged a partnership with Mexico City-based Total Quality Medicine (TQM). The agreement will bring OneOme’s pharmacogenomic (PGx) testing and support services to patients in Mexico, as TQM incorporates OneOme’s RightMed PGx test into its GeneTest line of personalized medicine products.

MINNEAPOLIS (June 15, 2017) – OneOme today launched a product update that makes improvements to its RightMed® pharmacogenomic test workflow, report and interactive application. OneOme’s updates incorporate customer feedback to optimize its product, with the goal of bringing the power of pharmacogenomics into everyday clinical care.

MINNEAPOLIS (May 31, 2017) – Pharmacogenomic company OneOme announced today it is working with leading health institutions on the nation’s largest population-based pharmacogenomics study.